[144] Guardant Health, Inc. SEC Filing

Rhea-AI Filing Summary

Guardant Health, Inc. (GH) filed a Form 144 notice for a planned sale of restricted stock that recently vested. The filing discloses that 3,213 shares of GH common stock are expected to be sold through broker Charles Schwab & Co., Inc. on or about 18 June 2025. The estimated aggregate market value of the proposed sale is $158,947. Compared with the company’s 123,888,045 shares outstanding, the transaction represents roughly 0.0026 % of total shares, indicating a de-minimis impact on the public float.

The seller—identified in the filing as Musa Tariq—acquired the shares on 15 June 2025 via the lapse of restrictions on equity compensation. Over the past three months Mr. Tariq has sold an additional 348 shares of Guardant Health stock across three transactions, generating $14,910 in gross proceeds. No relationship to the issuer is specified in the document, and the form states that the filer is unaware of any non-public material adverse information.

Because Form 144 covers proposed sales under Rule 144 and does not obligate the insider to complete the trade, investors typically view such filings as information events rather than firm commitments. Given the small size of the sale relative to Guardant Health’s market capitalization, the filing is unlikely to exert material pressure on share price but does provide incremental insight into insider trading intentions.

Positive

• Sale represents only 0.0026% of shares outstanding, limiting any dilution or liquidity impact.
• Filing compliance with Rule 144 enhances transparency and aligns with good governance practices.

Negative

• Insider intends to sell $158,947 worth of shares, which could be interpreted by some investors as a modest bearish signal.
• No 10b5-1 plan date disclosed, leaving execution timing at the insider’s discretion and potentially raising questions about trading windows.

Insights

Equity Research Analyst

TL;DR: Small insider sale (0.0026% of shares) signals routine liquidity event; negligible valuation impact.

The planned disposition of 3,213 shares worth about $159k is immaterial against Guardant Health’s 124 million-share base. The shares stem from recently vested equity compensation, a common post-vesting monetization move. While any insider sale can raise sentiment questions, the micro-scale and disclosed Rule 144 protocol point to a standard liquidity trade rather than a directional view on fundamentals. I classify the filing as neutral for valuation and liquidity.

Corporate Governance Specialist

TL;DR: Filing offers transparency; volume too small to alter governance risk profile.

Form 144 provides advance notice, enhancing disclosure quality. The seller has complied with Rule 144 timing and aggregation requirements, and the cumulative three-month sales (348 shares) plus planned 3,213 shares remain well below the 1% volume ceiling. No 10b5-1 plan date is listed, so execution discretion remains, but the adherence to Rule 144 demonstrates procedural conformity. From a governance lens, I see no red flags and minimal risk implications.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	3213	158947.00	123888045	06/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/15/2025	Restricted Stock Lapse	Guardant Health, Inc.			3213	06/15/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Musa Tariq 3100 HANOVER STREET PALO ALTO CA 94304	Guardant Health, Inc.	03/19/2025	116	5069.00
Musa Tariq 3100 HANOVER STREET PALO ALTO CA 94304	Guardant Health, Inc.	04/17/2025	116	5196.00
Musa Tariq 3100 HANOVER STREET PALO ALTO CA 94304	Guardant Health, Inc.	05/19/2025	116	4645.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Guardant Health (GH) shares are being sold under this Form 144?

The filer proposes to sell 3,213 common shares.

What is the estimated market value of the planned GH insider sale?

The aggregate market value is approximately $158,947.

When is the approximate sale date for the GH shares?

The shares are slated for sale on or about 18 June 2025.

How significant is the sale relative to Guardant Health’s total shares outstanding?

It represents roughly 0.0026 % of the 123,888,045 shares outstanding—an immaterial amount.

Who is the seller named in the Form 144 filing for GH?

The filing lists Musa Tariq as the person for whose account the securities are to be sold.

Were there prior GH stock sales by the same insider in the last three months?

Yes. The insider sold 348 shares in three transactions between March and May 2025, totaling $14,910 in gross proceeds.